Myasthenia Gravis: Cyclic and Continuous Dosing of Intravenous Efgartigimod
Elena Cortes, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain present in this MEDtalk the results of the ADAPT NXT study. This study analyze the efficacy, safety, and tolerability of 10 mg/kg intravenous efgartigimod administered in a cyclic or continuous dosing regimen.